Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫藥集團有限公司
China Resources Pharmaceutical Group Limited
(Incorporated in Hong Kong with limited liability)
(Stock Code: 3320)

ANNOUNCEMENT

PRINCIPAL OPERATING RESULTS ESTIMATE OF JIANGZHONG PHARMACEUTICAL FOR THE YEAR ENDED 31 DECEMBER 2025

On 23 January 2026, Jiangzhong Pharmaceutical released its unaudited preliminary financial information for the year ended 31 December 2025.

China Resources Jiangzhong Pharmaceutical Co., Ltd. (華潤江中藥業股份有限公司) ("**Jiangzhong Pharmaceutical**") is a company incorporated in the People's Republic of China. The shares of Jiangzhong Pharmaceutical are listed on the Shanghai Stock Exchange. As of the date of this announcement, Jiangzhong Pharmaceutical is owned as to approximately 43.14% equity interest by China Resources Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") through its non-wholly owned subsidiary, China Resources Jiangzhong Pharmaceutical Group Co., Ltd(華潤江中製藥集團有限責任公司). The Group controls an effective interest of approximately 26.12% of Jiangzhong Pharmaceutical, which is accounted for as a subsidiary of the Company.

On 23 January 2026, Jiangzhong Pharmaceutical released its unaudited preliminary financial information for the year ended 31 December 2025 (the "**Reporting Period**") (the "**Jiangzhong Pharmaceutical Preliminary Financial Information**"). Set out below are the key financial information of the Jiangzhong Pharmaceutical Preliminary Financial Information:

I. MAJOR FINANCIAL INFORMATION AND INDICATORS FOR THE YEAR OF 2025 (UNAUDITED)

Unit: RMB ten thousand

Item	**The Reporting Period**	**The corresponding period of previous year**	**Increase/ decrease (%)**
Total operating revenue	421,950	443,545	-4.87%
Operating profit	119,851	102,830	16.55%
Total profit	121,230	102,561	18.20%
Net profit attributable to the shareholders of the listed company	90,612	78,819	14.96%
Net profit attributable to the shareholders of the listed company (exclude extraordinary gains or losses)	83,235	74,918	11.10%
Basic earnings per share *(RMB)*	1.43	1.25	14.40%
Weighted average return on net asset *(%)*	22.74	19.58	+3.16 percentage point

Item	**As of the end of the Reporting Period**	**As of the beginning of the Reporting Period**	**Increase/ decrease (%)**
Total assets	687,659	650,794	5.66%
Equity attributable to the shareholders of the listed company	402,271	386,281	4.14%
Share capital	63,495	62,902	0.94%
Net assets per share attributable to the shareholders of the listed company *(RMB)*	6.34	6.14	3.17%

Note: The above information for this Reporting Period is based on information from unaudited consolidated financial statements. Any difference in the above increase or decrease figures is due to rounding.

II. DETAILS OF OPERATING RESULTS AND FINANCIAL POSITIONS

During the reporting period, in the face of structural adjustment pressure in the industry, Jiangzhong Pharmaceutical continued to strengthen brand building and fortified the foundation of its core business around "large single products and strong categories". In addition, Jiangzhong Pharmaceutical enriched marketing strategies, strengthened investment returns, optimized expense structures, and deepened lean manufacturing, promoting reduction in costs and increase in efficiency, and facilitating improvement of profitability.

In 2025, Jiangzhong Pharmaceutical achieved operating income of RMB4.220 billion, representing a year-on-year decrease of 4.87% and achieved a net profit attributable to shareholders of the listed company of RMB906 million, representing a year-on-year increase of 14.96%.

The Jiangzhong Pharmaceutical Preliminary Financial Information have been prepared in accordance with the PRC Generally Accepted Accounting Principles and are unaudited. The final audited results for the Reporting Period to be disclosed by Jiangzhong Pharmaceutical in its 2025 annual report shall prevail.

The financial information is limited to Jiangzhong Pharmaceutical only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the Jiangzhong Pharmaceutical Audited Annual Financials, please refer to the annual report for the year ended 31 December 2025 to be published by Jiangzhong Pharmaceutical on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 23 January 2026

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive Director, Mr. Cheng Jie and Mr. Liu Changan as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive Directors.